These can be useful parameters to establish recent reticulocyte stimulation of reticulocytes in response to rHuEpo
usage contrasting with results seen in normal physiologic RBC production.
was discontinued after six weeks of treatment; Hb was 12.
Kirin began marketing a rHuEPO
preparation, brand name ESPO(R) INJECTION, for the treatment of renal anemia in 1990, which has contributed greatly to the care of dialysis patients with renal anemia.
The general approach to detecting blood doping is to use indirect methods for screening and more specific methods for firm evidence of exogenous rHuEPO
Very little is known about the time course of urinary rHuEPO
after its administration.
Most of the exercise training studies in people with ESRD occurred before the use of rhuEPO
The finding of higher sEpo levels in FA and TI patients may indicate that rHuEpo
is unbeneficial in these diseases.
A high-dose regimen of RHuEPO
40,000 units per day with intravenous iron sucrose 100 mg per day was initiated.
After purifying isoforms of rHuEPO
, Egrie and coworkers (5,6) discovered a direct correlation between the number of sialic acid groups on the carbohydrate part of rHuEPO
and both its serum half-life and biological activity, as well as an inverse relationship with receptor binding.
is a substance made by the kidney which stimulates red blood cell production and is given to more than 90 percent of ESRD Medicare beneficiaries (Powe et al.
Multiple myeloma is another target market we aim to address with our rHuEPO
CHr has been shown to be a sensitive and specific indicator of functional ID in healthy individuals (29) and in patients with end-stage renal failure treated with rHuEPO
(18,19, 30, 31, 35).